Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755932 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT05755932 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 35 participants.
The verdict
NCT05755932, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
A Study to Assess the Effect of the HFO MDI Propellant on Mucociliary Clearance Compared to the HFA MDI Propellant in Healthy Participants
Interventions
- DRUG HFO-1234ze(E)
- DRUG HFA-134a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2024-07-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755932
The ClinicalTrials.gov registry entry for NCT05755932 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HFO-1234ze(E) is the first listed.
NCT05755932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05755932 about?
NCT05755932 is a clinical study titled "Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants". A Study to Assess the Effect of the HFO MDI Propellant on Mucociliary Clearance Compared to the HFA MDI Propellant in Healthy Participants
What is the current status of trial NCT05755932?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2023-06-14. Estimated completion is 2024-07-22.
What interventions are being tested in trial NCT05755932?
The interventions under investigation include: HFO-1234ze(E) (DRUG), HFA-134a (DRUG).
Who is sponsoring clinical trial NCT05755932?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.